Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de Michael Mendelsohn
Age : 66
Public asset : 1,784 USD
Country of residence : Unknown
Linked companies : Takeda Pharmaceutical Company Limited - Foghorn Therapeutics Inc. - Cyclerion Therapeutics, Inc.

Biography of Michael Mendelsohn 
Dr. Michael E. Mendelsohn, MD, is an Independent Director at Cyclerion Therapeutics, Inc., an Independent Director at Foghorn Therapeutics, Inc., a Chairman at Cardurion Pharmaceuticals LLC, a Chief Medical & Scientific Officer at Takeda Pharmaceutical Co., Ltd. and a President at Mendelsohn Consulting Group LLC. He is on the Board of Directors at Cyclerion Therapeutics, Inc. and Foghorn Therapeutics, Inc. Dr. Mendelsohn was previously employed as a President & Chief Scientific Officer by Ironwood Pharmaceuticals, Inc., a Venture Partner by SV Life Sciences Managers LLP, an Independent Director by Regado Biosciences, Inc., a Senior VP & Global Head-Cardiovascular Research by Merck Research Laboratories Massachusetts LLC, an Executive Director-MCRI by Tufts Medical Center, Inc., and a Chief Scientific Officer by Tufts University School of Medicine. He received his undergraduate degree from Amherst College and a doctorate degree from Harvard Medical School.


Current positions of Michael Mendelsohn 
Holdings of Michael Mendelsohn 
Michael Mendelsohn : Personal Network 
Most Read News 
05/20XAVIER NIEL : UWR shares spike as billionaire Xavier Niel discloses 27% stake
RE
05/12MASAYOSHI SON : SoftBank Vision Fund posts $26 billion loss; Son pledges defence
RE
05/14ELON MUSK : Elon Musk says Twitter legal team told him he violated an NDA
RE
05/24ELON MUSK : In a faceoff with Elon Musk, the SEC blinked
RE
05/19ELON MUSK : Musk says 'Tesla is on my mind 24/7' amid concerns about Twitter distraction
RE
05/17ELON MUSK : Prominent hedge funds invested in Twitter before Musk unveiled plans
RE
05/25ELON MUSK : Twitter investors vote against re-electing Elon Musk ally to board
RE
05/23HOCK TAN : Chipmaker Broadcom in talks to acquire VMware for $60 billion -sources
RE
05/17JPMorgan shareholders vote disapproval of CEO Dimon's special payout
RE
05/12ELON MUSK : Twitter CEO says two leaders to depart, hiring paused amid Musk takeover
RE
More news


© 2022 People and Ownership :   
Michael Mendelsohn : Connections 


Latest news about Michael Mendelsohn 
2020TRANSCRIPT : Cyclerion Therapeutics, Inc. - Shareholder/Analyst Call
CI
2019Cyclerion Therapeutics, Inc. Announces Executive Changes
CI
2019The Board of Directors of Ironwood Pharmaceuticals, Inc. completed the spin-off of Cyclerion Therapeutics, Inc.
CI
2018The Board of Directors of Ironwood Pharmaceuticals, Inc. announced the spin-off of soluble guanylate cyclase business.
CI
More news